CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the ...
CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsule ...
A soft sensor for colonoscopes has achieved 92 % accuracy in bleeding detection, improving safety during gastrointestinal ...
Monitoring symptoms, recognizing unusual changes taking place in the body and following screening guidelines are among the ...
Discover the groundbreaking capsule endoscopy—a tiny, wireless camera encased in a transparent pill-sized capsule. This ...
Celiac disease is an immune-mediated enteropathy triggered by gluten in genetically predisposed individuals (HLA-DQ2/DQ8), with a global seroprevalence of approximately 1.4%. However, only one in four ...
Q4 2025 earnings call: 15% revenue growth, $3.9M sales, CapsoCam Colon Gen 2/AI 510(k) timing, trials & funding—read now.
According to the American Cancer Society, colorectal cancer is one of the leading causes of cancer in men and women.
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Katie Okamoto Katie Okamoto is an editor focusing on sustainability. She’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results